<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sofosbuvir: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sofosbuvir: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sofosbuvir: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="91794" href="/d/html/91794.html" rel="external">see "Sofosbuvir: Drug information"</a> and <a class="drug drug_patient" data-topicid="91898" href="/d/html/91898.html" rel="external">see "Sofosbuvir: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F54153323"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Sofosbuvir-Containing Products Safety Review</span>
<span class="collapsible-date">January 2021</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Health Canada has reviewed the potential risk of severe cutaneous adverse reactions (SCAR) with the use of sofosbuvir-containing products and concluded that there may be a link between the use of sofosbuvir-containing products and the risk of Stevens Johnson syndrome (SJS), but did not confirm a link with the risk of other types of SCAR (eg, erythema multiforme, toxic epidermal necrolysis). Health Canada will work with manufacturers to update the Canadian product safety information for sofosbuvir-containing products to include the risk of SJS.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fhpr-rps.hres.ca%2Freg-content%2Fsummary-safety-review-detail.php%3Flang%3Den%26linkID%3DSSR00256&amp;token=uyEWVzucjoU0bip5ys9O%2BA2c8PExFbeHpd4oMCD3%2BAd6ANUAQ03qpAg40Yb70qLH1WHJohRLzUa6hgoUNqt%2BX%2F7YvaBPYgwnDucdS1PXCPQdhiK02TDMwbm%2Fo1toUxU8rwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=113353" target="_blank">https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00256</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F49809947"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hepatitis B virus reactivation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with sofosbuvir. HBV reactivation has been reported in hepatitis C virus (HCV)/HBV co-infected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV co-infected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F23009983"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sovaldi</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871702"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Sovaldi</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F50110956"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihepaciviral, Polymerase Inhibitor (Anti-HCV)</span>;</li>
<li>
<span class="list-set-name">NS5B RNA Polymerase Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F49956254"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Prior to initiating therapy, test patient for evidence of hepatitis B infection (current or prior).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b3d4f32-236e-44bd-86b3-f266758e607c">Chronic hepatitis C infection; treatment-naive or treatment-experienced without cirrhosis or with compensated cirrhosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis C infection (monoinfection or coinfected with HIV-1); treatment-naive or treatment-experienced without cirrhosis or with compensated cirrhosis (Child-Pugh class A): Note:</b> Use in combination with ribavirin. Treatment-experienced refers to patients who have failed prior treatment with an interferon-based regimen with or without ribavirin. Sofosbuvir dosage reduction is not recommended; however, other hepatitis C treatments (eg, ribavirin) may require dosage adjustments for toxicity. If other hepatitis C treatments require discontinuation due to toxicity, then discontinue sofosbuvir as well.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;17 kg: Pellets: Oral: 150 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">17 to &lt;35 kg: Pellets, tablets: Oral: 200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥35 kg: Pellets, tablets: Oral: 400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Treatment duration based on genotype:</p>
<p style="text-indent:-2em;margin-left:8em;">Genotype 2: 12 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">Genotype 3: 24 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51160230"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥3 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling. Predominant metabolite accumulates (up to 20-fold) in impaired renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">End stage renal disease, including hemodialysis patients: There are no dosage adjustments provided in the manufacturer's labeling. Predominant metabolite accumulates (up to 20-fold) in impaired renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">Dialysis: During a 4-hour dialysis session, 18% of sofosbuvir dose was removed.</p></div>
<div class="block dohp drugH1Div" id="F51160231"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥3 years and Adolescents: Mild, moderate, or severe impairment: No dosage adjustment necessary.</p></div>
<div class="block doa drugH1Div" id="F23632820"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="91794" href="/d/html/91794.html" rel="external">see "Sofosbuvir: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16cca722-a1a6-4d17-8ffa-869e415681a6">Chronic hepatitis C</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis C (CHC):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Genotype 3, peginterferon + ribavirin treatment–experienced patients with compensated cirrhosis (Child-Pugh class A) (alternative agent): </i>
<b>Oral:</b> 400 mg once daily with concomitant elbasvir/grazoprevir for 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AASLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AASLD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>All genotypes, patients with prior glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir treatment failure, without cirrhosis or with compensated cirrhosis (Child-Pugh class A):</i>
<b>Oral:</b> 400 mg once daily in combination with ribavirin and glecaprevir/pibrentasvir for 16 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AASLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AASLD.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990344"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Estimated glomerular filtration rate (eGFR) ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Predominant metabolite accumulates in impaired renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">End stage renal disease (ESRD), including hemodialysis patients: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Predominant metabolite accumulates in impaired renal function.</p></div>
<div class="block doha drugH1Div" id="F50987712"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild, moderate, or severe impairment (Child-Pugh class A, B, or C): No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F23081823"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported with combination therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (11% to 27%), skin rash (8% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (18%), diarrhea (9% to 12%), nausea (22% to 34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (6% to 21%), neutropenia (&lt;1% [interferon-free regimen] to 17% [interferon-containing regimen])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (2% to 17%), fatigue (30% to 59%), headache (24% to 36%), insomnia (15% to 25%), irritability (10% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (5% to 21%), myalgia (6% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (6% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (4% to 18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Increased serum lipase (&gt;3 times ULN: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (&gt;2.5 times ULN: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased creatine phosphokinase in blood specimen (≥10 times ULN: 1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Severe depression, suicidal ideation</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome (Verma 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Lactic acidosis (Smith 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Reactivation of HBV</p></div>
<div class="block coi drugH1Div" id="F22901520"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's labeling. When administered with ribavirin and peginterferon alfa, the contraindications to ribavirin and peginterferon alfa also apply. See Ribavirin and Peginterferon Alfa monographs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to sofosbuvir or any component of the formulation; males whose female partners may become pregnant</p></div>
<div class="block war drugH1Div" id="F23621995"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Rapid reduction in hepatitis C viral load during direct-acting antiviral (DAA) therapy for hepatitis C may lead to improvement in glucose metabolism in patients with diabetes, potentially resulting in symptomatic hypoglycemia if antidiabetic agents are continued at the same dose. Monitor for changes in glucose tolerance and inform patients of the risk of hypoglycemia during DAA therapy, particularly within the first 3 months. Modification of antidiabetic therapy may be necessary (Ciancio 2018; Dawood 2017; Hum 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatitis B virus reactivation: <b>[US Boxed Warning]: Hepatitis B virus (HBV) reactivation has been reported in hepatitis C virus (HCV)/HBV co-infected patients who were receiving or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy; some cases have resulted in fulminant hepatitis, hepatic failure, and death. Test all patients for evidence of current or prior HBV infection prior to initiation of sofosbuvir; monitor HCV/HBV co-infected patients for hepatitis flare or HBV reactivation during treatment and post-treatment follow-up. Initiate treatment for HBV infection as clinically indicated. </b>HBV reactivation has been reported in HBsAg positive patients and in patients with serologic evidence of resolved HBV infection (ie, HBsAg negative and anti-HBc positive) and is characterized by an abrupt increase in HBV replication manifested as a rapid increase in serum HBV DNA level; reappearance of HBsAg may occur in patients with resolved HBV infection. Risk of HBV reactivation may be increased in patients receiving certain immunosuppressants or chemotherapeutic agents.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Amiodarone: Symptomatic bradycardia (some requiring pacemaker intervention) has occurred in patients receiving amiodarone and a sofosbuvir-containing regimen. Fatal cardiac arrest occurred in a patient taking amiodarone and the ledipasvir/sofosbuvir combination product. Bradycardia generally occurred within hours to days following coadministration, however some cases have occurred 2 weeks following the initiation of sofosbuvir. The risk of bradycardia may be increased in patients taking beta blockers or patients with underlying cardiac comorbidities and/or advanced liver disease. Bradycardia generally resolves following discontinuation of HCV treatment. Coadministration of amiodarone and sofosbuvir in combination with another DAA is not recommended. However, if patients have no treatment alternatives, patients should have inpatient cardiac monitoring for the first 48 hours, followed by daily outpatient or self-monitoring of heart rate for at least the first 2 weeks of treatment. Due to the long half-life of amiodarone, cardiac monitoring (as described) is also recommended if amiodarone was discontinued just prior to beginning treatment with sofosbuvir. Patients should seek medical attention immediately if they experience fainting or near-fainting, dizziness, lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pains, confusion or memory problems.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Safety and efficacy have not been established in patients with decompensated cirrhosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do not use as monotherapy; use only as part of a multiple drug regimen for treatment of HCV; consult current HCV treatment guidelines for guidance (AASLD/IDSA 2021).</p></div>
<div class="block prod-avail drugH1Div" id="F53610940"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Sovaldi oral pellets: FDA approved August 2019; anticipated availability is currently unknown. Consult the prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F23009984"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sovaldi: 150 mg (28 ea); 200 mg (28 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sovaldi: 200 mg, 400 mg</p></div>
<div class="block geq drugH1Div" id="F23009982"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F23613371"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Sovaldi Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $1,200.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1,200.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sovaldi Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1,200.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $1,200.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871703"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sovaldi: 400 mg</p></div>
<div class="block admp drugH1Div" id="F52614553"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Pellets: Administer with or without food. May be sprinkled on 1 or more spoonfuls of non-acidic soft foods (eg, pudding, chocolate syrup, mashed potatoes, ice cream) at or below room temperature; gently mix. Swallow entire contents within 30 minutes of mixing; to avoid bitter aftertaste, do not chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Administer with or without food.</p></div>
<div class="block adm drugH1Div" id="F23622215"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Pellets: Administer with or without food. If administered without food, pour packet contents directly in the mouth and swallow without chewing to avoid bitter aftertaste; follow with water if needed. If administered with food, sprinkle packet contents on ≥1 spoonfuls of non-acidic soft foods (eg, pudding, chocolate syrup, mashed potatoes, ice cream) at or below room temperature; gently mix. Swallow entire contents within 30 minutes of mixing; do not chew to avoid bitter aftertaste.</p></div>
<div class="block sts drugH1Div" id="F23622016"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Tablets and pellets: Store below 30°C (86°F). Dispense only in original packaging.</p></div>
<div class="block usep drugH1Div" id="F53571121"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of genotype 2 or 3 chronic hepatitis C virus (HCV) infection, in combination with ribavirin, in patients without cirrhosis or with compensated cirrhosis (FDA approved in pediatric patients ≥3 years); treatment of genotype 1, 2, 3, or 4 chronic HCV infection without cirrhosis or with compensated cirrhosis as a component of a combination antiviral treatment regimen (FDA approved in adults).</p></div>
<div class="block cyt drugH1Div" id="F23081851"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, P-glycoprotein/ABCB1 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F23081848"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: Sofosbuvir may enhance the bradycardic effect of Amiodarone.  Management: Use alternative to a sofosbuvir-containing combo or to amiodarone when possible. If alternatives not possible, monitor in inpatient setting for first 48 hours of coadministration with daily outpatient monitoring for at least 2 weeks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Direct Acting Antiviral Agents (HCV) may enhance the hypoglycemic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: Sofosbuvir may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Modafinil: May decrease the serum concentration of Sofosbuvir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: May decrease the serum concentration of Sofosbuvir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Sofosbuvir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Sofosbuvir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of Sofosbuvir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Sofosbuvir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Sofosbuvir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Direct Acting Antiviral Agents (HCV) may decrease the serum concentration of Tacrolimus (Systemic). Direct Acting Antiviral Agents (HCV) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Sofosbuvir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Direct Acting Antiviral Agents (HCV) may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53633857"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients with hepatitis C virus (HCV) infection should be treated before considering pregnancy to optimize maternal health and reduce the risk of HCV transmission (AASLD/IDSA 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Sofosbuvir is not used as monotherapy; if used in combination with ribavirin or peginterferon, all warnings related to the use of ribavirin or peginterferon and contraception should be followed. Refer to the ribavirin and peginterferon monographs for additional information.</p></div>
<div class="block pri drugH1Div" id="F23621992"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on a placental perfusion study, GS-331007 (the main metabolite of sofosbuvir) is expected to cross the placenta (Freriksen 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Sofosbuvir is not used as monotherapy; combination therapy with ribavirin is contraindicated in pregnant patients and males whose partners are pregnant. If used in combination with ribavirin or peginterferon, all warnings related to the use of ribavirin or peginterferon and pregnancy should be followed. Refer to the ribavirin and peginterferon monographs for additional information.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of sofosbuvir and other direct-acting antiviral (DAA) medications during pregnancy are limited. Use of a DAA is not currently recommended for the purpose of reducing mother to child transmission of hepatitis C virus due to a lack of safety and efficacy data. The decision to continue treatment in a patient who becomes pregnant while taking a DAA should be individualized after considering the potential benefits and risks of therapy. DAA medications should not be initiated during pregnancy outside of clinical trials until safety and efficacy data are available (AASLD/IDSA 2021; AbdAllah 2021; Mandimika 2019; SMFM [Dotters-Katz 2021]).</p></div>
<div class="block mopp drugH1Div" id="F53571122"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Management of hepatitis C virus (HCV) infection requires extensive monitoring; refer to current guidelines for additional guidance including response to abnormal laboratory parameters (AASLD/IDSA 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Baseline (within 12 weeks prior to starting antiviral therapy): CBC, INR, hepatic function panel (albumin, total and direct bilirubin, ALT, AST, and alkaline phosphatase), SCr, calculated GFR. Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) prior to initiation; in patients with serologic evidence of hepatitis B virus (HBV) infection, monitor for clinical and laboratory signs of hepatitis flare or HBV reactivation during treatment and during post-treatment follow-up. HCV genotype and subtype, quantitative HCV viral load (at any time prior to starting antiviral therapy) (AASLD/IDSA 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">During therapy: CBC, SCr, calculated GFR, hepatic function panel (after 4 weeks of therapy and as clinically indicated); quantitative HCV viral load testing (after 4 weeks of therapy and at 12 weeks after completion of therapy). If quantitative HCV viral load is detectable at treatment week 4, repeat testing is recommended after 2 additional weeks of treatment (treatment week 6) (AASLD/IDSA 2018). If used in combination with amiodarone (or in patients who discontinued amiodarone just prior to initiating sofosbuvir), inpatient cardiac monitoring for the first 48 hours of coadministration, then daily outpatient or self-monitoring of heart rate through at least the first 2 weeks of treatment.</p></div>
<div class="block pha drugH1Div" id="F23622017"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sofosbuvir, a direct-acting antiviral agent against the hepatitis C virus, is a prodrug converted to its pharmacologically active form (GS-461203) via intracellular metabolism.  It inhibits HCV NS5B RNA-dependent RNA polymerase, essential for viral replication, and acts as a chain terminator.</p></div>
<div class="block phk drugH1Div" id="F23622019"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>The pharmacokinetic profile in pediatric patients ≥3 years of age is similar to adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~61% to 65%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; forms pharmacologically active nucleoside (uridine) analog triphosphate GS-461203; dephosphorylation results in the formation of nucleoside inactive metabolite GS-331007</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 0.4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~0.5 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80%; primarily as metabolite); feces (14%)</p></div>
<div class="block phksp drugH1Div" id="F51221450"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC<sub>0-∞</sub> was higher in mild (eGFR ≥50 and &lt;80 mL/minute/1.73 m<sup>2</sup>), moderate (eGFR ≥30 and &lt;50 mL/minute/1.73 m<sup>2</sup>), and severe (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>) renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC<sub>0-24</sub> was higher in moderate and severe hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45783728"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Anisovir | Evaldix | Ferasin | Fozvir | Hepagris | Pemutol | Probirase | Sovaldi | Ultrabuvir</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Hopetavir | Sofovir c | Soventa | Suvirux</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Sophir | Sovaldi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Andohepasuvir | Augispov | Episovir | Grateziano | Gratisovir | Heterosofir | Hopforhep | Magicbuvir | Mpiviropack | Myhep | Nucleobuvir | Serinospirevir | Sofocivir | Sofodelevier | Sofohep | Sofolanork | Sofomerase | Soforoyal | Sofosbuvir biomed | Sofozav | Sovaldi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Hepcinat | Hepcivir | Nucleobuvir | Sovihep | Virso</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Hepcinat | Myhep</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cimivir | Hepcinat | Hepcvir | Myhep | Novisof | Resof | Sofab | Sofocure | Sofokem | Sofovir | Sovihep | Viroclear | Zosovir</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Myhep | Sovaldi</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Hepcinat | Myhep | Sovaldi</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Isof | Sophos | Ssb 400</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi | Virso</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Grateziano | Hepcinat | Hepcvir | Myhep | Sofgen</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Myhep</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Abriva | Basovir | C off | Chc | Cure c | Hep c vir | Hepaldi | Hepcinat | Hepcvir | Hepgard | Lesof | Myhep | Novus | Ocvir | Ozbir | Qvir | Safaldi | Saferon | Savera | Scihop | Sobvi | Sofhep | Sofiget | Sofohil | Sofomac | Sofonil | Sofos | Sofotel | Sovaldi | Sovihep | Sovir | Vebuvir | Vibrenta | Virohep | Virso | Ziqar | Zoval</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Probirase</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi | Sovira</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Myhep | Sovaldi</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ebuvir | Myhep</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Sovaldi</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Grateziano | Hepcinat | Myhep | Sofgen | Sovaldi | Virso</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Myhep | Sofgen | Sovaldi | Sovihep</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Biancal | Sovaldi</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Soravir</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Myhep | Sofgen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33905164">
<a name="33905164"></a>AbdAllah M, Alboraie M, Abdel-Razek W, et al. Pregnancy outcome of anti-HCV direct-acting antivirals: real-life data from an Egyptian cohort. <i>Liver Int.</i> 2021;41(7):1494-1497. doi:10.1111/liv.14913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/33905164/pubmed" id="33905164" target="_blank">33905164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AASLD.1">
<a name="AASLD.1"></a>American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA). HCV guidance: recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org. Updated October 5, 2021. Accessed March 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28960353">
<a name="28960353"></a>Ciancio A, Bosio R, Bo S, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. <i>J Med Virol.</i> 2018;90(2):320-327. doi:10.1002/jmv.24954.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/28960353/pubmed" id="28960353" target="_blank">28960353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28868829">
<a name="28868829"></a>Dawood AA, Nooh MZ, Elgamal AA. Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4. <i>Diabetes Metab J</i>. 2017;41(4):316-321. doi: 10.4093/dmj.2017.41.4.316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/28868829/pubmed" id="28868829" target="_blank">28868829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16401485">
<a name="16401485"></a>Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. <i>Gastroenterology</i>. 2006;130(1):225-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/16401485/pubmed" id="16401485" target="_blank">16401485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34116035">
<a name="34116035"></a>Dotters-Katz SK, Kuller JA, Hughes BL. Society for Maternal-Fetal Medicine Consult Series #56: hepatitis C in pregnancy-updated guidelines: replaces Consult Number 43, November 2017. <i>Am J Obstet Gynecol</i>. 2021;225(3):B8-B18. doi:10.1016/j.ajog.2021.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/34116035/pubmed" id="34116035" target="_blank">34116035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA Safety Alert. MedWatch. Direct-acting antiviral for hepatitis C: drug safety communication – risk of hepatitis B reactivating. Food and Drug Administration website. Available at <a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm523690.htm" target="_blank">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm523690.htm</a>. Accessed December 8, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26535533">
<a name="26535533"></a>Fontaine H, Lazarus A, Pol S, et al. Bradyarrhythmias associated with sofosbuvir treatment. <i>N Engl J Med</i>. 2015;373(19):1886-1888.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/26535533/pubmed" id="26535533" target="_blank">26535533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32877661">
<a name="32877661"></a>Freriksen JJM, Meijerhof M, van Drongelen J, et al. Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo. <i>Am J Obstet Gynecol</i>. 2020;223(6):941-943. doi:10.1016/j.ajog.2020.08.107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/32877661/pubmed" id="32877661" target="_blank">32877661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28659309">
<a name="28659309"></a>Hum J, Jou JH, Green PK, et al. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. <i>Diabetes Care</i>. 2017;40(9):1173-1180. doi: 10.2337/dc17-0485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/28659309/pubmed" id="28659309" target="_blank">28659309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31645394">
<a name="31645394"></a>Mandimika C, Ogbuagu O. Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV. <i>BMJ Case Rep.</i> 2019;12(10):e230529. doi:10.1136/bcr-2019-230529<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/31645394/pubmed" id="31645394" target="_blank">31645394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31361914">
<a name="31361914"></a>Smith ZR, Horng M, Rech MA. Medication-induced hyperlactatemia and lactic acidosis: a systematic review of the literature. <i>Pharmacotherapy</i>. 2019;39(9):946-963.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/31361914/pubmed" id="31361914" target="_blank">31361914</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sovaldi (sofosbuvir) [prescribing information]. Foster City, CA; Gilead Sciences Inc; March 2020.</div>
</li>
<li>
<div class="reference">
                  Sovaldi (sofosbuvir) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29404508">
<a name="29404508"></a>Verma N, Singh S, Sawatkar G, Singh V. Sofosbuvir induced Steven Johnson Syndrome in a patient with hepatitis C virus-related cirrhosis. <i>Hepatol Commun</i>. 2017;2(1):16-20. doi:10.1002/hep4.1126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/29404508/pubmed" id="29404508" target="_blank">29404508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sofosbuvir-pediatric-drug-information/abstract-text/26042815/pubmed" id="26042815" target="_blank">26042815</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 113353 Version 109.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
